Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)

The Washington University

Status: Completed

Conditions: Head and Neck Cancer Survivors; Cancer of the Head and Neck Surviors

Treatments: Other: Ototoxicity Screening Protocol

Study type: Interventional

Funder types: Other

Identifiers

NCT05789316

202302038

Details and patient eligibility

About

To evaluate the effectiveness, feasibility, acceptability, and appropriateness of an ototoxicity screening protocol among head and neck (H&N) cancer patients followed in survivorship clinic that received cisplatin-based chemoradiation therapy (CRT).

Enrollment: 55 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult (≥ 18 years old)
• H&N cancer patients will be eligible for inclusion if they have previously undergone cisplatin-based CRT or radiotherapy, including proton therapy, intensity-modulated radiation therapy, and adaptive radiotherapy-surgery with curative intent (i.e., definitive, neoadjuvant, or adjuvant) or definitive surgery with neoadjuvant or adjuvant radiation.

Exclusion criteria

• Patient has been evaluated by an audiologist within the past 12 months
• Use of a hearing aid
• Received a cochlear implant
• Cannot complete simple forms in English

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

55 participants in 1 patient group

Ototoxicity Screening Protocol

Experimental group

Description:

After enrollment, participants will complete a pre-screening survey. Before their survivorship clinic visit, participants will complete the ototoxicity screening protocol and implementation outcome surveys. During their visit, they will receive counseling on ototoxicity and referral to audiology. After their visit, they will complete the SESMQ and WU-QOLv4 surveys and undergo pure tone audiometry. Each participant will complete this protocol once. The investigators will follow each participant by chart review for at least six months to evaluate for audiologic follow-up.

Treatment:

Other: Ototoxicity Screening Protocol